These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9055142)

  • 1. Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus.
    Martin DE; DeCherney GS; Ilson BE; Jones BA; Boike SC; Freed MI; Jorkasky DK
    J Clin Pharmacol; 1997 Feb; 37(2):155-9. PubMed ID: 9055142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eprosartan does not affect the pharmacodynamics of warfarin.
    Kazierad DJ; Martin DE; Ilson B; Boike S; Zariffa N; Forrest A; Jorkasky DK
    J Clin Pharmacol; 1998 Jul; 38(7):649-53. PubMed ID: 9702851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension.
    Ilson BE; Martin DE; Boike SC; Jorkasky DK
    J Clin Pharmacol; 1998 May; 38(5):437-41. PubMed ID: 9602957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group.
    Hedner T; Himmelmann A
    J Hypertens; 1999 Jan; 17(1):129-36. PubMed ID: 10100104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study.
    Derosa G; Ragonesi PD; Mugellini A; Ciccarelli L; Fogari R
    Hypertens Res; 2004 Jul; 27(7):457-64. PubMed ID: 15302981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men.
    Ilson BE; Boike SC; Martin DE; Freed MI; Zariffa N; Jorkasky DK
    Clin Pharmacol Ther; 1998 Apr; 63(4):471-81. PubMed ID: 9585802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies.
    Blum RA; Kazierad DJ; Tenero DM
    Pharmacotherapy; 1999 Apr; 19(4 Pt 2):79S-85S. PubMed ID: 10213526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers.
    Martin DE; Tompson D; Boike SC; Tenero D; Ilson B; Citerone D; Jorkasky DK
    Br J Clin Pharmacol; 1997 Jun; 43(6):661-4. PubMed ID: 9205830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eprosartan: a review of its use in the management of hypertension.
    Plosker GL; Foster RH
    Drugs; 2000 Jul; 60(1):177-201. PubMed ID: 10929934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group.
    Gradman AH; Gray J; Maggiacomo F; Punzi H; White WB
    Clin Ther; 1999 Mar; 21(3):442-53. PubMed ID: 10321414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eprosartan.
    McClellan KJ; Balfour JA
    Drugs; 1998 May; 55(5):713-8; discussion 719-20. PubMed ID: 9585867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study.
    Punzi HA; Punzi CF
    J Hum Hypertens; 2004 Sep; 18(9):655-61. PubMed ID: 15042114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
    Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
    Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans.
    Osei SY; Price DA; Laffel LM; Lansang MC; Hollenberg NK
    Hypertension; 2000 Jul; 36(1):122-6. PubMed ID: 10904023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension.
    White WB; Anwar YA; Mansoor GA; Sica DA
    Am J Hypertens; 2001 Dec; 14(12):1248-55. PubMed ID: 11775134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevation of sympathetic activity by eprosartan in young male subjects.
    Heusser K; Vitkovsky J; Raasch W; Schmieder RE; Schobel HP
    Am J Hypertens; 2003 Aug; 16(8):658-64. PubMed ID: 12878372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
    Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
    Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eprosartan: an angiotensin-II receptor antagonist for the management of hypertension.
    Cheng-Lai A
    Heart Dis; 2002; 4(1):54-9. PubMed ID: 11975834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers.
    Tenero DM; Martin DE; Ilson BE; Boyle DA; Boike SC; Carr AM; Lundberg DE; Jorkasky DK
    Ann Pharmacother; 1998 Mar; 32(3):304-8. PubMed ID: 9533060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
    Levine B
    Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.